Seres Therapeutics effects 1-for-20 reverse stock split, effective April 21, 2025

Seres Therapeutics, Inc.

Reverse stock split at 1-for-20 ratio, effective 5:00 PM ET on April 21, 2025.
Common stock begins split-adjusted trading on Nasdaq on April 22, 2025 under symbol MCRB.
No fractional shares will be issued; holders receive cash in lieu of fractional shares.
Authorized shares and par value per share remain unchanged.
Stockholders approved split range of 1:5 to 1:50; Board fixed final ratio at 1:20.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Seres Therapeutics, Inc.: Effected a 1-for-20 reverse stock split of common stock by filing a Certificate of Amendment to the Restated Certificate of Incorporation (effective 2025-04-21).

Change: charter amendment
Effective: 2025-04-21

Exact text from the filing

On April 21, 2025, Seres Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Restated Certificate of Incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective April 21, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”).

View on SEC.gov

Browse all governance changes →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-089189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.